Release of angiogenic growth factors from cells encapsulated in alginate beads with bioactive glass
Source abstract
Abstract
Attempts to stimulate therapeutic angiogenesis using gene therapy or delivery of recombinant growth factors, such as vascular endothelial growth factor (VEGF), have failed to demonstrate unequivocal efficacy in human trials. Bioactive glass stimulates fibroblasts to secrete significantly increased amounts of angiogenic growth factors and therefore has a number of potential applications in therapeutic angiogenesis. The aim of this study was to assess whether it is possible to encapsulate specific quantities of bioactive glass and fibroblasts into alginate beads, which will secrete growth factors capable of stimulating angiogenesis. Human fibroblasts (CCD-18Co) were encapsulated in alginate beads with specific quantities of 45S5 bioactive glass and incubated in culture medium (0-17 days). The conditioned medium was collected and assayed for VEGF or used to assess its ability to stimulate angiogenesis by measuring the proliferation of human dermal microvascular endothelial cells. At 17 days the beads were lysed and the amount of VEGF retained by the beads measured. Fibroblasts encapsulated in alginate beads containing 0.01% and 0.1% (w/v) 45S5 bioactive glass particles secreted increased quantities of VEGF compared with cells encapsulated with 0% or 1% (w/v) 45S5 bioactive glass particles. Lysed alginate beads containing 0.01% and 0.1% (w/v) 45S5 bioactive glass contained significantly more VEGF (p<0.01) compared with beads containing no glass particles. Endothelial cell proliferation was significantly increased (p<0.01) by conditioned medium collected from alginate beads containing 0.1% (w/v) 45S5 bioactive glass particles. The results of this study demonstrate that bioactive glass and fibroblasts can be successfully incorporated into alginate beads for use in delivering angiogenic growth factors. With further optimization, this technique offers a novel delivery device for stimulating therapeutic angiogenesis.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Spine and Intervertebral Disc Pathology · Hemostasis and retained surgical items
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Therapeutic angiogenesis in cardiovascular disease10.1038/nrd1226 ↗
2. Role of vascular endothelial growth factor in regulation of physiological angiogenesis10.1152/ajpcell.2001.280.6.C1358 ↗
3. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs10.1161/01.CIR.89.5.2183 ↗
4. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis10.1038/nm1095-1085 ↗
5. Vascular endothelial growth factor administration in chronic myocardial ischemia
6. VEGF administration in chronic myocardial ischemia in pigs10.1016/S0008-6363(98)00136-9 ↗
7. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts10.1006/jsre.1996.0226 ↗
8. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease10.1067/mhj.2001.118471 ↗
9. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion10.1161/01.CIR.101.2.118 ↗
10. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease10.1016/S0003-4975(99)00807-3 ↗
11. Angiogenesis gene therapy10.1161/01.CIR.100.5.468 ↗
12. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia10.1161/01.CIR.0000015982.70785.B7 ↗
13. VIVA Investigators. The VIVA trial10.1161/01.CIR.0000061911.47710.8A ↗
14. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients10.1016/S0002-9149(03)00661-1 ↗
15. Therapeutic angiogenesis. Devising new strategies based on past experiences10.1007/s00395-004-0447-x ↗
16. Angiogenesis therapy10.1161/01.CIR.104.1.115 ↗
17. Clinical applications of angiogenic growth factors and their inhibitors10.1038/70928 ↗
18. Therapeutic angiogenesis10.1136/bmj.318.7197.1536 ↗
19. Bonding mechanisms at the interface of ceramic prosthestic materials10.1002/jbm.820050611 ↗
20. Hench · Bioceramics. J Am Ceram Soc · 1998 · 81 · 170510.1111/j.1151-2916.1998.tb02540.x ↗
21. In vivo evaluation of a bioactive scaffold for bone tissue engineering10.1002/jbm.10157 ↗
22. Day R. Bioglass® stimulates the secretion of angiogenic growth factors and angiogenesis. Tissue Eng 2005, in press.10.1089/ten.2005.11.768 ↗
23. Assessment of polyglycolic acid mesh and bioactive glass for soft tissue engineering scaffolds10.1016/j.biomaterials.2004.01.043 ↗
24. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells10.1016/0014-4886(91)90022-5 ↗
25. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression10.1172/JCI118929 ↗
26. Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics10.1067/mlc.2002.120649 ↗
27. Alginate dressings in surgery and wound management—Part 110.12968/jowc.2000.9.2.26338 ↗
28. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture10.3727/095535491820873191 ↗
29. Use of the CytoTox 96™ Assay in routine biocompatibility testing in vitro
30. Broad-spectrum bactericidal activity of Ag(2)O-doped bioactive glass10.1128/AAC.46.6.1940-1945.2002 ↗
31. Release from alginate enhances the biological activity of vascular endothelial growth factor10.1163/156856298X00389 ↗
32. Sustained delivery of vascular endothelial growth factor with alginate beads10.1016/j.jconrel.2004.02.021 ↗
33. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor10.1046/j.1525-1594.2001.025007558.x ↗
34. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy10.1093/emboj/21.8.1939 ↗
35. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease10.1016/S1050-1738(02)00259-1 ↗
36. Interindividual heterogeneity in the hypoxic regulation of VEGF10.1161/01.CIR.100.5.547 ↗
37. The well-tempered vessel10.1038/87850 ↗
38. Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release10.1002/jbm.a.10061 ↗
39. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres10.1002/jbm.a.10542 ↗
40. In vitro kinetics of insulin release by microencapsulated rat islets10.1007/BF00279134 ↗
41. Prospects for delivery of recombinant angiostatin by cell-encapsulation therapy10.1089/104303403769211646 ↗
42. Systems for therapeutic angiogenesis in tissue engineering10.1007/PL00007070 ↗
43. A review of therapeutic angiogenesis and consideration of its potential applications to plastic and reconstructive surgery10.1054/bjps.2000.3454 ↗
44. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-110.1053/gast.2001.29308 ↗
45. Effect of recombinant adeno-associated virus vectormediated vascular endothelial growth factor gene transfer on wound healing after burn injury10.1097/01.CCM.0000059435.88283.C2 ↗